Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 12 12:40PM ET
13.88
Dollar change
-0.27
Percentage change
-1.93
%
IndexRUT P/E- EPS (ttm)-2.48 Insider Own16.76% Shs Outstand53.81M Perf Week-0.38%
Market Cap746.69M Forward P/E- EPS next Y-3.97 Insider Trans0.00% Shs Float44.79M Perf Month-20.06%
Income-131.83M PEG- EPS next Q-1.00 Inst Own94.76% Short Float17.99% Perf Quarter-37.24%
Sales133.35M P/S5.60 EPS this Y20.56% Inst Trans3.25% Short Ratio15.08 Perf Half Y-35.06%
Book/sh9.93 P/B1.40 EPS next Y-81.19% ROA-19.64% Short Interest8.06M Perf Year-59.03%
Cash/sh9.65 P/C1.44 EPS next 5Y34.07% ROE-22.90% 52W Range13.22 - 41.54 Perf YTD-61.81%
Dividend Est.- P/FCF- EPS past 5Y6.83% ROI-24.27% 52W High-66.60% Beta0.07
Dividend TTM- Quick Ratio11.52 Sales past 5Y4680.14% Gross Margin87.28% 52W Low4.97% ATR (14)0.98
Dividend Ex-Date- Current Ratio11.52 EPS Y/Y TTM-77.69% Oper. Margin-126.12% RSI (14)40.00 Volatility5.91% 7.44%
Employees173 Debt/Eq0.02 Sales Y/Y TTM-5.41% Profit Margin-98.86% Recom1.50 Target Price59.00
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q-390.42% Payout- Rel Volume0.30 Prev Close14.15
Sales Surprise-27.98% EPS Surprise5.78% Sales Q/Q-98.86% EarningsNov 13 BMO Avg Volume534.15K Price13.88
SMA20-4.98% SMA50-13.63% SMA200-32.99% Trades Volume81,775 Change-1.93%
Date Action Analyst Rating Change Price Target Change
Jan-30-24Downgrade BofA Securities Buy → Neutral $68 → $38
Dec-12-23Initiated Deutsche Bank Buy $62
Apr-24-23Initiated SVB Securities Outperform $80
Jan-27-23Initiated Piper Sandler Overweight $94
Nov-04-22Downgrade RBC Capital Mkts Outperform → Sector Perform $52 → $55
Sep-28-22Upgrade BofA Securities Neutral → Buy
Nov-19-21Initiated JMP Securities Mkt Outperform $77
Jun-18-21Upgrade BofA Securities Underperform → Neutral $12 → $49
Jun-08-21Reiterated Oppenheimer Outperform $45 → $54
May-26-21Initiated Citigroup Buy $39
Today 11:30AM
Nov-12-24 05:55PM
04:56PM
04:05PM
Nov-05-24 04:05PM
12:00PM Loading…
Oct-29-24 12:00PM
04:48AM
Oct-18-24 03:01PM
Sep-27-24 04:05PM
Aug-29-24 04:05PM
Aug-19-24 12:00PM
Aug-18-24 12:28AM
Aug-17-24 08:22AM
Aug-09-24 09:16AM
Aug-08-24 06:40PM
05:33PM Loading…
05:33PM
04:05PM
Aug-01-24 04:05PM
Jul-25-24 10:02AM
Jun-24-24 08:48AM
Jun-11-24 04:07PM
12:20PM
Jun-07-24 11:30AM
May-29-24 10:26AM
08:46AM
May-28-24 04:05PM
May-09-24 11:52AM
May-08-24 10:56PM
06:10PM
05:14PM
04:05PM Loading…
04:05PM
May-01-24 04:05PM
Apr-25-24 10:01AM
Apr-15-24 04:05PM
Mar-28-24 08:00AM
Mar-05-24 04:05PM
Mar-04-24 04:05PM
Feb-21-24 04:05PM
Feb-16-24 01:33PM
10:33AM
Feb-15-24 04:50PM
04:48PM
04:05PM
Feb-08-24 04:05PM
Jan-24-24 11:02PM
Jan-10-24 12:06PM
05:38AM
Jan-08-24 08:30AM
Dec-21-23 09:01AM
Dec-17-23 05:41AM
Dec-01-23 11:05AM
Nov-29-23 08:35AM
Nov-20-23 06:00AM
Nov-17-23 01:35PM
08:15AM
Nov-03-23 11:34AM
Nov-02-23 07:03PM
06:25PM
05:24PM
04:05PM
Oct-30-23 10:00AM
Oct-26-23 04:09PM
04:05PM
10:02AM
05:02AM
Oct-18-23 11:20AM
Oct-17-23 07:57AM
Oct-16-23 11:54AM
11:42AM
Oct-12-23 05:01AM
Oct-07-23 03:33PM
Oct-05-23 09:01AM
Sep-28-23 05:01AM
Sep-19-23 09:01PM
Sep-14-23 01:32PM
Sep-07-23 12:00PM
Aug-31-23 04:05PM
Aug-04-23 09:13AM
Aug-03-23 05:55PM
04:49PM
04:05PM
Aug-02-23 07:57AM
Jul-27-23 04:05PM
Jul-18-23 05:36PM
05:36PM
11:30AM
Jul-17-23 08:35AM
Jul-13-23 09:22AM
Jul-11-23 04:05PM
08:59AM
Jul-10-23 04:10PM
Jul-07-23 09:51AM
Jun-27-23 04:05PM
Jun-12-23 09:25AM
Jun-08-23 12:41PM
Jun-02-23 04:05PM
May-16-23 04:05PM
May-10-23 06:13AM
May-05-23 12:27PM
May-04-23 06:45PM
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walker Karin LChief Accounting OfficerJan 24 '24Option Exercise13.535,00067,6505,000Jan 24 07:01 PM
Walker Karin LChief Accounting OfficerJan 24 '24Sale34.005,000170,0000Jan 24 07:01 PM
Walker Karin LChief Accounting OfficerDec 20 '23Option Exercise13.535,00067,6505,000Dec 20 07:17 PM
Walker Karin LChief Accounting OfficerDec 20 '23Sale37.195,000185,9520Dec 20 07:17 PM